Hanover - Delayed Quote EUR

Valneva SE (AYJ.HA)

2.7260

+0.0020

+(0.07%)

As of 8:01:20 AM GMT+2. Market Open.

Valneva reports data from Phase II chikungunya vaccine trial in children

The Phase II trial was funded in part by the CEPI, with support from the EU.

Clinical Trials Arena 2 days ago

VLA.PA
Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®

IXCHIQ® was well tolerated by children aged one to eleven years regardless of the dose or previous chikungunya infection (CHIKV)Antibody levels remained high after six months in both dose groups, although more robust with the full doseSix-month data confirm full dose selection for pivotal Phase 3 trial Saint-Herblain (France), June 5, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive six-month antibody persistence and safety data for its

GlobeNewswire 3 days ago

INRLF

VALN
[Valneva SE] Declaration of shares and voting rights - May 2025

VALNEVA Declaration of shares and voting rights May 31, 2025__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: June 5, 2025 Number of shares composing the share capital of Valneva Total number of voting rights including suspended voting rights* Description of the change Date on which this change was

GlobeNewswire 4 days ago

INRLF

VALN
Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update

Saint-Herblain (France), June 4, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company (“the Company”), today announced the availability of documentation for its Combined General Meeting (“the Meeting”) to be held on June 25, 2025 at 2:00 p.m. CEST at the Sofitel Lyon Bellecour Hotel, 20 quai du Docteur Gailleton, 69002 Lyon (France). The Preliminary Notice of Meeting – including the agenda, the draft resolutions proposed by the Board of Directors, and instructions f

GlobeNewswire 5 days ago

INRLF

VALN
Valneva to Participate at U.S. and European Investor Conferences in June

Saint-Herblain (France), May 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and hold investor meetings at several upcoming investor conferences in the United States and Europe in June 2025. Key topics for discussion include Valneva’s commercial stage vaccines and its differentiated portfolio of vaccine candidates, including VLA15, the world’s leading Lyme disease vaccine candidate. VLA15 is partnered

GlobeNewswire 13 days ago

INRLF

VALN
High Growth Tech Stocks In Europe With Promising Potential

The European market has shown resilience, with the pan-European STOXX Europe 600 Index rising for a fourth consecutive week amid optimism over easing trade tensions between China and the U.S., while Germany's DAX and Italy's FTSE MIB posted gains. In this environment of cautious economic optimism, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation capabilities, adaptability to changing trade dynamics, and robust financial health to navigate...

Simply Wall St. 26 days ago

ALGIF

INRLF

VALN
Valneva’s chikungunya vaccine use halted in older adults amid safety concerns

Both the FDA and EMA have suspended Ixchiq’s use in older adults after post-marketing serious adverse events that include two deaths.

Pharmaceutical Technology 27 days ago

VLA.PA
Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States

Saint Herblain (France), May, 12 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the U.S. Food and Drug Association (FDA) and the U.S. Centers for Disease Control and Prevention (CDC), in a joint communication to the medical community, have recommended a pause in the use of Valneva’s single-dose live attenuated chikungunya vaccine IXCHIQ® in elderly individuals while ongoing investigations into reported serious adverse events (SAEs) are co

GlobeNewswire 28 days ago

INRLF

VALN
Eli Lilly extends Purdue alliance; EMA investigates Valneva shot

The big pharma will spend up to $250 million over the next eight years of the collaboration. Elsewhere, CRISPR Therapeutics unveiled new data and Vivo Capital raised funds.

BioPharma Dive 30 days ago

LLY

CRL

VLA.PA
Valneva SE (INRLF) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Operational ...

Valneva SE (INRLF) reports a significant increase in product sales and revenue, despite facing operational losses and ongoing safety investigations.

GuruFocus.com last month

VLA.PA
VALNEVA Declaration of shares and voting rights: April 30, 2025

VALNEVA Declaration of shares and voting rights April 30, 2025__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: May 7, 2025 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the change Date on which this change was r

GlobeNewswire last month

INRLF

VALN
Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly

Saint Herblain (France), May, 07 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) has started a review of Valneva’s single-dose live attenuated chikungunya vaccine IXCHIQ® based on reports of serious adverse events (SAEs) in elderly people. As a temporary measure, while this review is ongoing, EMA has suspended the use of the vaccine for individuals over 65 years old. EMA has maintained current recommenda

GlobeNewswire last month

INRLF

VALN
Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Total revenues of €49.2 million compared to €32.8 million in the first quarter of 2024Cash and cash equivalents of €153.0 million at end of March 2025Further clinical and regulatory progress2025 financial outlook confirmed Saint-Herblain (France), May 7, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its financial results for the first quarter ending March 31, 2025, provided key corporate updates and confirmed its 2025 financial guidance. The c

GlobeNewswire last month

INRLF

VALN
France halts Valneva’s chikungunya vaccine use in seniors

The move follows reports of serious adverse events, including one death, among elderly vaccine recipients.

Pharmaceutical Technology last month

VLA.PA
Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities

Saint Herblain (France), April 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that France’s national public health agency, the Haute Autorité de Santé (HAS), has updated its recommendation for use of Valneva’s single-dose chikungunya vaccine IXCHIQ® for the prevention of disease caused by the chikungunya virus (CHIKV) following reports of serious adverse events (SAEs) in elderly people with comorbidities during the ongoing vaccination camp

GlobeNewswire last month

INRLF

VALN
Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers

Saint Herblain (France), April 18, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that during its regular meeting on April 16, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) updated its recommendation for use of Valneva’s single-dose chikungunya vaccine IXCHIQ® for the prevention of disease caused by the chikungunya virus (CHIKV). ACIP maintained its current recommendation for IX

GlobeNewswire last month

INRLF

VALN
Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ®

Saint-Herblain (France), April 16, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its presence at the forthcoming 25th World Vaccine Congress, which will take place from April 21-24, 2025 at the Walter E. convention center in Washington, D.C. Under the leadership of the Company´s Chief Executive Officer, Thomas Lingelbach, a team of Valneva´s senior managers will participate in multiple events, including an important presentation on the Compan

GlobeNewswire last month

INRLF

VALN
Valneva’s single-dose chikungunya vaccine authorised in Brazil

The authorisation paves the way for clinical studies to begin.

Pharmaceutical Technology last month

VLA.PA
Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country

Saint Herblain (France), April 14, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted marketing authorization to its single-dose vaccine IXCHIQ® for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. The ANVISA decision marks the world’s first approval of a chikungunya vaccine in an endemic country. Part of Valneva’s endemic country str

GlobeNewswire last month

INRLF

VALN
VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study

Valneva intends to test its experimental Shigella vaccine in nearly 110 infants. Results from this study are expected later this year.

Zacks last month

VLA.PA

CTMX

ANIP

Performance Overview

Return	AYJ.HA	CAC 40 (^FCHI)
YTD	+22.68%	+5.69%
1-Year	-30.14%	-2.52%
3-Year	-76.30%	+22.68%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Valneva SE (AYJ.HA)

Valneva reports data from Phase II chikungunya vaccine trial in children

Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®

[Valneva SE] Declaration of shares and voting rights - May 2025

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update

Valneva to Participate at U.S. and European Investor Conferences in June

High Growth Tech Stocks In Europe With Promising Potential

Valneva’s chikungunya vaccine use halted in older adults amid safety concerns

Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States

Eli Lilly extends Purdue alliance; EMA investigates Valneva shot

Valneva SE (INRLF) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Operational ...

VALNEVA Declaration of shares and voting rights: April 30, 2025

Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly

Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates

France halts Valneva’s chikungunya vaccine use in seniors

Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities

Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers

Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ®

Valneva’s single-dose chikungunya vaccine authorised in Brazil

Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country

VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study

Performance Overview